Boston Scientific (BSX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific (BSX) is backing a pilot trial called “Combined CM and STN Stimulation for Motor Epilepsy,” which tests whether pairing two brain targets can better control seizures in adults who do not respond to drugs. The goal is to see if this new deep brain stimulation approach can improve movement related epilepsy and open a path to a niche but important growth area in neuromodulation.
The study uses an implanted deep brain stimulation device designed for people with drug resistant motor epilepsy. One setting stimulates a region called the centromedian thalamus, while the other setting adds stimulation of the subthalamic nucleus, aiming to fine tune brain signals that drive seizures and reduce disabling motor symptoms.
The trial is an interventional study with patients randomly assigned to different stimulation settings over time in a self crossover design. It is double blind for both patients and investigators, which means neither side knows which pattern is active at a given time, and the main goal is to test treatment benefit rather than just observe outcomes.
The study is listed as not yet recruiting, with initial submission dated March 4, 2026, signaling the formal start of the setup phase. The most recent update on March 9, 2026, shows that the protocol is active and refined, while primary and final completion dates are still ahead and will mark when key efficacy and safety data become available.
For investors, this update reinforces Boston Scientific’s push to deepen its neuromodulation pipeline beyond pain and movement disorders, which could support long term revenue diversification and higher margins if results are positive. Competition from device peers in epilepsy, such as NeuroPace and Medtronic, is real, but a strong showing here could boost BSX’s perceived innovation edge and support sentiment in a premium valuation environment.
The study remains in the early, ongoing stage with details and future updates available on the ClinicalTrials portal.
To learn more about BSX’s potential, visit the Boston Scientific drug pipeline page.